This new, one-two punch could knock out drug-resistant TB

A recent study has demonstrated that rifampicin (a frontline antibiotic for TB) when paired with a second compound called AAP-SO₂, becomes a more powerful treatment in both suppressing TB resistance and targeting the dormant TB bacteria that other medications struggle to attack. This potential new treatment could help shift TB drug development towards a more precision medicine approach, especially as drug resistant-TB continues to be a worldwide issue. Read more here.